脂質異常症患者におけるAZD0780の異なる用量の有効性、安全性および忍容性を評価する研究

基本情報

NCT ID

NCT06173570

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

428

治験依頼者名

AstraZeneca

概要

The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.

対象疾患

介入

依頼者（Sponsor）